Our Pricing

Buy Wegovy Online with Fast Prescription Service

Published on: June 03, 2026

When you buy Wegovy online UK prescription services through Cured Pharmacy, you access genuine UK-licensed semaglutide injections from £79.00, supported by a free clinical consultation completed in under three minutes. Our UK-registered prescribers assess your eligibility, and we deliver discreetly to your door with transparent upfront pricing.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [1]. This medication works by slowing gastric emptying, reducing appetite signals to the brain, and improving insulin sensitivity — three complementary mechanisms that support sustainable weight reduction when combined with lifestyle modifications.

In the STEP 1 clinical trial involving 1,961 adults with obesity, participants using semaglutide 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 86.4% of semaglutide-treated patients lost at least 5% of their baseline weight, meeting the clinical threshold for meaningful health improvement.

Semaglutide's once-weekly subcutaneous injection offers practical advantages over daily treatments. The medication reaches steady-state concentration after approximately four to five weeks of dose escalation, with effects sustained throughout the seven-day dosing interval [2].

Wegovy Dosing Schedule and Titration Protocol

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. Your UK prescriber will typically start you on 0.25mg weekly for the first month, gradually increasing every four weeks through 0.5mg, 1mg, and 1.7mg, before reaching the maintenance dose of 2.4mg [2].

This gradual titration allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation. Clinical data demonstrates that patients who complete the full escalation schedule experience significantly fewer treatment discontinuations due to nausea or vomiting compared to accelerated protocols [3].

What to Expect During Dose Escalation

During your first four weeks on the 0.25mg starter dose, you may notice subtle appetite reduction, though significant weight loss typically begins after reaching higher doses. Most patients report the most pronounced effects on hunger and portion control between the 1mg and 2.4mg doses, which corresponds with peak clinical efficacy observed in trial data [1][3].

Wegovy Eligibility Criteria in the UK

To buy Wegovy online UK prescription services require clinical assessment against MHRA-approved criteria. Your prescriber will evaluate whether you meet the licensed indications: adults with a body mass index (BMI) of 30 kg/m² or greater, or BMI 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [4].

Your medical history review will identify contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy complications. Pregnancy and breastfeeding are absolute contraindications, and women of childbearing potential should use reliable contraception during treatment [4].

Our clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), conducts thorough assessments to ensure Wegovy represents an appropriate and safe option based on your individual health profile and weight management goals.

Wegovy vs Saxenda: Comparing GLP-1 Weight Loss Treatments

Both Wegovy and Saxenda are GLP-1 receptor agonists licensed in the UK for weight management, but they differ significantly in active ingredient, dosing frequency, and clinical efficacy profiles. Wegovy contains semaglutide administered once weekly, whilst Saxenda contains liraglutide requiring daily subcutaneous injection.

Head-to-head clinical data demonstrates superior weight reduction with semaglutide. In the STEP 8 trial, semaglutide 2.4mg weekly produced 15.8% average weight loss compared to 6.4% with liraglutide 3mg daily over 68 weeks [5]. This substantial difference reflects semaglutide's longer half-life (approximately one week versus 13 hours) and greater receptor binding affinity.

Treatment choice depends on individual factors including injection preference, side effect tolerance, and previous GLP-1 experience. Your UK prescriber will discuss which option aligns best with your lifestyle and clinical needs during your consultation.

Practical Differences Between Weekly and Daily Injections

The once-weekly Wegovy injection offers convenience advantages for patients with busy schedules or injection anxiety, requiring only 52 injections annually versus 365 with daily Saxenda. However, some patients prefer daily dosing for more granular control over side effects, particularly during initial treatment phases when gastrointestinal symptoms are most common.

Managing Wegovy Side Effects: Evidence-Based Strategies

Gastrointestinal side effects represent the most common treatment-emergent adverse events with Wegovy, affecting approximately 44% of patients in clinical trials [1]. Nausea, diarrhoea, vomiting, and constipation typically emerge during dose escalation and diminish as treatment continues, with most cases classified as mild to moderate in severity.

Practical management strategies can significantly improve tolerability. Eating smaller, more frequent meals rather than three large meals helps accommodate slowed gastric emptying. Avoiding high-fat foods, which delay gastric emptying further, reduces nausea intensity. Staying well-hydrated and consuming fibre-rich foods helps manage both constipation and diarrhoea.

If side effects persist despite these measures, your prescriber may recommend extending the time at your current dose before escalating, or in some cases, reducing to the previous tolerated dose. Clinical trial data shows that treatment discontinuation due to gastrointestinal events occurred in only 4.5% of participants, indicating most patients successfully manage these effects [1].

When to Contact Your Prescriber

Seek immediate medical advice if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to the back), or symptoms of gallbladder disease. These serious but uncommon events require prompt clinical evaluation and may necessitate treatment discontinuation [4].

Buy Wegovy Online UK: What to Expect from Cured Pharmacy

When you buy Wegovy online UK prescription services through Cured Pharmacy, the process begins with a comprehensive clinical questionnaire covering your medical history, current medications, weight management goals, and previous treatment attempts. Our UK-registered prescribers review your submission within hours, typically the same working day.

If approved, we dispense genuine UK-licensed Wegovy pens sourced directly from licensed wholesalers, never grey-market imports. Your medication arrives in 100% discreet packaging with no external pharmacy branding, delivered via tracked courier to your specified address. Each pen includes patient information leaflets and injection technique guidance.

Our pricing remains transparent from your first click — you'll see the £79.00 starting cost before beginning your consultation, with no hidden fees or subscription requirements. This straightforward approach reflects our commitment to accessible, honest healthcare delivery across the UK.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.